MY147436A - Process for the synthesis of 5-(methyl-1h-imidazol-1-yl)-3-(trifluoromethyl-benzeneamine - Google Patents

Process for the synthesis of 5-(methyl-1h-imidazol-1-yl)-3-(trifluoromethyl-benzeneamine

Info

Publication number
MY147436A
MY147436A MYPI20062507A MYPI20062507A MY147436A MY 147436 A MY147436 A MY 147436A MY PI20062507 A MYPI20062507 A MY PI20062507A MY PI20062507 A MYPI20062507 A MY PI20062507A MY 147436 A MY147436 A MY 147436A
Authority
MY
Malaysia
Prior art keywords
benzeneamine
imidazol
trifluoromethyl
synthesis
methyl
Prior art date
Application number
MYPI20062507A
Other languages
English (en)
Inventor
Joseph Mckenna
Wen-Chung Shieh
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MY147436A publication Critical patent/MY147436A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Steroid Compounds (AREA)
MYPI20062507A 2005-06-09 2006-05-31 Process for the synthesis of 5-(methyl-1h-imidazol-1-yl)-3-(trifluoromethyl-benzeneamine MY147436A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68897705P 2005-06-09 2005-06-09
US70559005P 2005-08-04 2005-08-04

Publications (1)

Publication Number Publication Date
MY147436A true MY147436A (en) 2012-12-14

Family

ID=37091153

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20062507A MY147436A (en) 2005-06-09 2006-05-31 Process for the synthesis of 5-(methyl-1h-imidazol-1-yl)-3-(trifluoromethyl-benzeneamine

Country Status (31)

Country Link
US (2) US8124763B2 (https=)
EP (1) EP1924574B1 (https=)
JP (1) JP5118024B2 (https=)
KR (3) KR101216249B1 (https=)
AR (1) AR053890A1 (https=)
AT (1) ATE487709T1 (https=)
AU (1) AU2006258051B2 (https=)
BR (1) BRPI0611663A2 (https=)
CA (1) CA2610105C (https=)
CY (1) CY1111428T1 (https=)
DE (1) DE602006018156D1 (https=)
DK (1) DK1924574T3 (https=)
EC (1) ECSP077982A (https=)
EG (1) EG25039A (https=)
GT (1) GT200600217A (https=)
IL (1) IL187421A (https=)
JO (1) JO2636B1 (https=)
MA (1) MA29599B1 (https=)
MX (1) MX2007015423A (https=)
MY (1) MY147436A (https=)
NO (1) NO340743B1 (https=)
NZ (1) NZ563740A (https=)
PE (1) PE20070015A1 (https=)
PL (1) PL1924574T3 (https=)
PT (1) PT1924574E (https=)
RU (1) RU2444520C2 (https=)
SA (1) SA06270147B1 (https=)
SI (1) SI1924574T1 (https=)
TN (1) TNSN07463A1 (https=)
TW (1) TWI430999B (https=)
WO (1) WO2006135641A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200600316A (es) * 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
US8242271B2 (en) 2007-06-04 2012-08-14 Avila Therapeutics, Inc. Heterocyclic compounds and uses thereof
EP2305667A3 (en) 2008-07-17 2011-05-11 Teva Pharmaceutical Industries Ltd. Nilotinib intermediates and preparation thereof
EP2262793B1 (en) 2008-11-05 2012-10-03 Teva Pharmaceutical Industries Ltd. Nilotinib hci crystalline forms
WO2010060074A1 (en) * 2008-11-24 2010-05-27 Teva Pharmaceutical Industries Ltd. Preparation of nilotinib and intermediates thereof
US20110053968A1 (en) 2009-06-09 2011-03-03 Auspex Pharmaceuticals, Inc. Aminopyrimidine inhibitors of tyrosine kinase
JO3634B1 (ar) 2009-11-17 2020-08-27 Novartis Ag طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r
EP2691539B1 (en) 2011-03-31 2018-04-25 The Procter and Gamble Company Methods for identifying and evaluating skin-active agents effective for treating dandruff
AR086913A1 (es) * 2011-06-14 2014-01-29 Novartis Ag 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
GB2514285B (en) 2012-02-13 2018-07-18 Grindeks Jsc Intermediates for a novel process of preparing imatinib and related tyrosine kinase inhibitors
US9920357B2 (en) 2012-06-06 2018-03-20 The Procter & Gamble Company Systems and methods for identifying cosmetic agents for hair/scalp care compositions
WO2015092624A1 (en) 2013-12-16 2015-06-25 Ranbaxy Laboratories Limited Nilotinib mono-oxalate and its crystalline form
CN103694176B (zh) 2014-01-07 2015-02-18 苏州立新制药有限公司 尼洛替尼中间体的制备方法
EP3095782A1 (en) 2015-05-18 2016-11-23 Esteve Química, S.A. New method for preparing 3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)benzenamine
EP3749697A4 (en) 2018-02-05 2021-11-03 Bio-Rad Laboratories, Inc. CHROMATOGRAPHY RESIN WITH LIGAND MIXED MODE ANIONIC / HYDROPHOBIC EXCHANGE
CN113292537B (zh) 2018-06-15 2024-04-05 汉达癌症医药责任有限公司 激酶抑制剂的盐类及其组合物
JP2020007240A (ja) * 2018-07-04 2020-01-16 住友化学株式会社 ベンズアミド化合物の製造方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5136082A (en) * 1990-08-03 1992-08-04 Himont Incorporated Process for preparing organic esters and amides and catalyst system therefor
CA2151491A1 (en) 1992-12-24 1994-07-07 Robert J. Kaufman Fluorocarbon emulsions
TW406020B (en) 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
US5597829A (en) 1994-05-09 1997-01-28 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of camptothecin and methods for uses thereof
US5726181A (en) 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US6323366B1 (en) 1997-07-29 2001-11-27 Massachusetts Institute Of Technology Arylamine synthesis
AR013261A1 (es) 1997-08-01 2000-12-13 Smithkline Beecham Corp Formulaciones farmaceuticas para analogos de camptotecina en capsula de gelatina
US20030059465A1 (en) 1998-05-11 2003-03-27 Unger Evan C. Stabilized nanoparticle formulations of camptotheca derivatives
US6395916B1 (en) 1998-07-10 2002-05-28 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
ATE216998T1 (de) 1999-03-09 2002-05-15 Sigma Tau Ind Farmaceuti Camptothecin-derivate mit antitumor-wirkung
IT1306129B1 (it) 1999-04-13 2001-05-30 Sigma Tau Ind Farmaceuti Esteri della l-carnitina o di alcanoil l-carnitine utilizzabili comelipidi cationici per l'immissione intracellulare di composti
DE19926056B4 (de) 1999-06-08 2004-03-25 Gkss-Forschungszentrum Geesthacht Gmbh Einrichtung zur Analyse atomarer und/oder molekularer Elemente mittels wellenlängendispersiver, röntgenspektrometrischer Einrichtungen
GB9918885D0 (en) 1999-08-10 1999-10-13 Pharmacia & Upjohn Spa Pharmaceutical formulations in hydroxypropymethycellulose capsules
GB9925127D0 (en) 1999-10-22 1999-12-22 Pharmacia & Upjohn Spa Oral formulations for anti-tumor compounds
US20040009229A1 (en) 2000-01-05 2004-01-15 Unger Evan Charles Stabilized nanoparticle formulations of camptotheca derivatives
US20020150615A1 (en) 2001-02-12 2002-10-17 Howard Sands Injectable pharmaceutical composition comprising microdroplets of a camptothecin
US6629598B2 (en) 2001-08-10 2003-10-07 Vinod K. Narula Flexible ribbed splint system
US6653319B1 (en) 2001-08-10 2003-11-25 University Of Kentucky Research Foundation Pharmaceutical formulation for poorly water soluble camptothecin analogues
WO2003032906A2 (en) 2001-10-15 2003-04-24 Crititech, Inc. Delivery of poorly soluble drugs
AU2002353118A1 (en) 2001-12-11 2003-07-24 Dor Biopharma, Inc. Lipid particles and suspensions and uses thereof
JP2003267891A (ja) 2002-03-13 2003-09-25 Mitsubishi-Kagaku Foods Corp W/o/w型エマルション製剤
US7202367B2 (en) 2002-05-31 2007-04-10 Rhodia Chimie Process for arylating or vinylating or alkynating a nucleophilic compound
CZ294371B6 (cs) 2002-06-10 2004-12-15 Pliva - Lachema, A. S. Stabilizovaná farmaceutická kompozice na bázi polyoxyethylovaného ricinového oleje a způsob její přípravy
EP1393719A1 (en) 2002-08-23 2004-03-03 Munich Biotech AG Camptothecin-carboxylate formulations
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
JP4426749B2 (ja) 2002-07-11 2010-03-03 株式会社産学連携機構九州 O/w型エマルション製剤
US20040171560A1 (en) 2002-12-23 2004-09-02 Dabur Research Foundation Stabilized pharmaceutical composition
JP2006199590A (ja) 2003-09-04 2006-08-03 Nano Career Kk 水溶性の塩基性薬物内包ナノ粒子含有組成物
BRPI0415858A (pt) 2003-10-29 2007-01-09 Sonus Pharma Inc compostos de medicamentos terapêuticos modificados por tocoferol
WO2005060871A1 (en) 2003-12-17 2005-07-07 Bionumerik Pharmaceuticals, Inc. Pharmaceutical formulations of camptothecins and process for making same
GT200500310A (es) 2004-11-19 2006-06-19 Compuestos organicos

Also Published As

Publication number Publication date
KR20120066067A (ko) 2012-06-21
IL187421A0 (en) 2008-02-09
KR20130118394A (ko) 2013-10-29
SA06270147B1 (ar) 2009-12-22
ATE487709T1 (de) 2010-11-15
JP5118024B2 (ja) 2013-01-16
US20120116081A1 (en) 2012-05-10
MA29599B1 (fr) 2008-07-01
TWI430999B (zh) 2014-03-21
EP1924574A2 (en) 2008-05-28
NZ563740A (en) 2011-03-31
CA2610105A1 (en) 2006-12-21
KR101514593B1 (ko) 2015-04-22
TNSN07463A1 (en) 2009-03-17
TW200726756A (en) 2007-07-16
CY1111428T1 (el) 2015-08-05
NO20080157L (no) 2008-01-09
GT200600217A (es) 2007-03-28
KR101216249B1 (ko) 2012-12-28
RU2007148231A (ru) 2009-07-20
US8124763B2 (en) 2012-02-28
AU2006258051B2 (en) 2010-09-09
PT1924574E (pt) 2011-02-08
AU2006258051A1 (en) 2006-12-21
PE20070015A1 (es) 2007-02-06
HK1117524A1 (en) 2009-01-16
JP2008545786A (ja) 2008-12-18
ECSP077982A (es) 2008-01-23
US8946416B2 (en) 2015-02-03
JO2636B1 (en) 2012-06-17
DK1924574T3 (da) 2011-02-14
CA2610105C (en) 2014-03-25
PL1924574T3 (pl) 2011-04-29
AR053890A1 (es) 2007-05-23
KR20080022093A (ko) 2008-03-10
EP1924574B1 (en) 2010-11-10
DE602006018156D1 (de) 2010-12-23
WO2006135641A3 (en) 2007-03-29
IL187421A (en) 2011-11-30
MX2007015423A (es) 2008-02-21
NO340743B1 (no) 2017-06-12
RU2444520C2 (ru) 2012-03-10
BRPI0611663A2 (pt) 2010-09-28
US20080188656A1 (en) 2008-08-07
SI1924574T1 (sl) 2011-02-28
WO2006135641A2 (en) 2006-12-21
EG25039A (en) 2011-07-06

Similar Documents

Publication Publication Date Title
TNSN07463A1 (en) Process for the synthesis of organic compounds
TW200624421A (en) Method for preparing n-phenylpyrazole-1-carboxamides
EA200701358A1 (ru) Кристаллические формы гидрохлорида (r)-8-хлор-1-метил-2,3,4,5-тетрагидро-1h-3-бензазепина
TW200626559A (en) Anilino-pyrimidine analogs
ATE442421T1 (de) Kohlenstoffhaltiges material
MX2009013591A (es) Proceso para la preparacion de pirazoles.
NO20073701L (no) Nye fremgangsmater for fremstilling av et 2H-kromen
TW200619215A (en) Asymmetric synthesis of dihydrobenzofuran derivatives
MX2007004698A (es) Sintesis asimetrica de dihidrobenzofuranos sustituidos.
MXPA05011962A (es) Oxiarenos substituidos.
EA200701470A1 (ru) Способы получения производных 4-(фенокси-5-метилпиримидин-4-илокси)пиперидин-1-карбоновой кислоты и родственных соединений
TW200643053A (en) Organoaluminum precursor compounds
NO20071253L (no) Fremgangsmate for syntese av C-2, C-3 substituerte N-alkylerte indoler anvendbare som CPLA2-inhibitorer.
NZ595579A (en) 5-Difluoromethoxy-4-hydroxymethyl-1-methyl-3-trifluoromethyl-pyrazole / (5-(difluoromethoxy)-3-(trifluoromethyl)-1-methyl-1H-pyrazol-4-yl)methanol
BRPI0607296A2 (pt) produção de 3-(alquiltio)propanal
TW200631939A (en) Process for cross coupling indoles
PT1877370E (pt) Método para produzir derivados hidrazona
CY1114798T1 (el) Ενωσεις σουλφοναμιδιου για τη θεραπευτικη αντιμετωπιση αναπνευστικων διαταραχων
TW200420537A (en) Process for the preparation of pyrrolidinyl ethylamine compounds via a copper-mediated aryl amination
IL189527A0 (en) Chemical process
DE602007009367D1 (de) Yl)-n-methylbenzylamin
MXPA05004262A (es) Proceso para elaborar compuestos de pirazol.
GB0328871D0 (en) Resolution process
TW200635940A (en) Process for preparing thiophene-glycoside derivatives
EP1818332A4 (en) PROCESS FOR PREPARING AN EPOXYTRIAZOL DERIVATIVE